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Abstract
Background: Interface pressure is a key risk factor in the development of pressure ulcers. Visual feedback of
continuous interface pressure between the body and support surface could inform clinicians on repositioning
strategies and play a key role in an overall strategy for the prevention and management of pressure ulcers.
Methods/Design: A parallel two-group randomized controlled clinical trial will be conducted to study the effect of
continuous pressure imaging on reducing interface pressure and on the incidence of pressure ulcers in vulnerable
hospital patients. A total of 678 eligible consenting inpatients at risk of pressure ulcer development in a tertiary
acute care institution will be randomly allocated to either having the ForeSite PT™ system with the liquid-crystal
display monitor turned on to provide visual feedback to the clinicians while also collecting continuous interface
pressure data (intervention group) or to having the ForeSite PT™ system with monitor turned off (that is, not
providing visual feedback) but still collecting continuous interface pressure data (control group), in a ratio of 1:1.
Continuous interface pressure data will be collected in both groups for 3 days (72 h). Data collection will continue
until discharge for a subset of approximately 60 patients. The primary outcome will be the differences in the two
groups’ interface pressure analysis. Interface pressure readings will be collected through hourly samplings of
continuous interface pressure recordings. Secondary outcomes will be the differences between the two groups in
pressure-related skin and soft tissue changes in areas at risk of pressure ulcer (obtained at baseline within 24 h of
admission) and on the third day of the trial or at discharge and perceptions of the intervention by patients and
clinicians (obtained on the third day or at discharge).
Discussion: This will be the first randomized controlled trial to investigate the effect of visual feedback with
continuous interface pressure of vulnerable hospital patients across different care settings, and the association
between interface pressure and development of pressure-related skin and soft tissue changes. The results could
provide important information to guide clinical practice in the prevention and management of pressure ulcers.
Trials registration: ClinicalTrials.gov NCT02325388 (date of registration: 24 December 2014).
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Background
Pressure ulcers are a leading cause of morbidity for in-
facility individuals [1] and lead to substantial discomfort,
prolonged hospitalizations, additional costs, and in some
cases death [2]. A pressure ulcer is defined as “a local-
ized injury to the skin and/or underlying tissue over a
bony prominence, as a result of pressure, or pressure in
combination with shear” [3]. Their severity varies from
skin erythema to full thickness tissue loss with damage
extending into muscle and bone [3]. Annually, pressure
ulcers affect an estimated 250,000 to 500,000 individuals
in Canada with an overall estimated prevalence of
26.0 % in healthcare institutions [1]. In Germany, the
prevalence rate is estimated to be 10 to 25 % among
ward patients and as high as 30 % in rehabilitation cen-
ters [4]. In one Austrian public hospital, incidence rates
were between 1.39 % and 7.98 % for Stage 1, 0.14 % and
1.52 % for Stage II, and 0 % and 0.88 % for Stage III
pressure ulcers [5].
More severe cases require intensive therapy, have lon-
ger healing times and are associated with a higher inci-
dence of complications [6]. In the United States, the
average hospital treatment cost associated with stage IV
pressure ulcers range from $124,327 to $129,248 USD
[7], whereas in the UK the estimated cost of treatment
varies from £1,214 to £14,108 per case [6]. Similar costs
are seen in Canada, where the estimated average
monthly cost of pressure ulcer management among indi-
viduals with a spinal cord injury in 2010 was $4,475
CDN [8].
The development of pressure ulcers is multifactorial.
General risk factors for their development include lim-
ited mobility and activity causing excessive interface
pressure between the skin and the supporting surface;
compromised tissue perfusion (associated with condi-
tions such as diabetes and anemia); a variety of skin con-
ditions; excessive skin moisture (for example, from
urinary incontinence); advanced age; malnutrition; and
poor general health status [9–11]. Additional predictors
of pressure ulceration among adults in the intensive care
unit (ICU) include admission duration, norepinephrine
administration and, the presence of cardiovascular
disease [12]. Among adults with spinal cord injuries,
delayed and/or inappropriate medical management,
history of or existing pressure ulceration and limited
independence in self-care are predictive of their de-
velopment [13].
Among at-risk individuals, pressure ulcers develop on
body areas exposed to unrelieved high interface pressure
over prolonged periods of time [14, 15]. If interface pres-
sure is higher than mean capillary blood pressure, blood
flow can be compromised, with the affected areas becom-
ing ischemic and necrotic if the duration of pressure is
sufficiently sustained [14]. Though commonly accepted
that an area becomes at-risk when interface pressure ex-
ceeds 30 to 32 mmHg [16–20], it must be emphasized that
the duration of the interface pressure is equally as import-
ant as the magnitude of the interface pressure.
As pressure applied over a prolonged period is a key
risk factor in the development of pressure ulcers, fre-
quent and regular repositioning of the patient is a com-
mon practice that has been recognized for decades as an
integral component of prevention and treatment proto-
cols [15]. To date, the published literature has es-
tablished neither repositioning nor the frequency of
repositioning to be effective at preventing and managing
pressure ulceration. One Cochrane systematic review
concluded that there is limited robust evidence on the
effectiveness of positioning and frequency of reposi-
tioning for pressure ulcer prevention [21]. Similarly, an-
other Cochrane review could not find any randomized
trials that assess the effectiveness of repositioning on
healing rates of pressure ulcers [22]. Thus while reposi-
tioning is rational and widely recommended, the lack of
robust evaluations of how repositioning alters interface
pressure has led to uncertainty and a clear need for
high-quality, adequately powered trials to assess different
approaches to the implementation of repositioning [21].
It is generally accepted that many pressure ulcers are
avoidable though there are also situations where they
cannot be prevented [23]. Due to the complexity of pres-
sure ulcer development, many acute and long-term care
facilities adopt multipronged, multidisciplinary interven-
tions to prevent pressure ulcers [24]. Current best prac-
tice guidelines recommend a standardized pressure ulcer
risk assessment [25]. The Braden Scale for Predicting
Pressure Sore Risk [26] (herein the “Braden Scale”) is the
most validated with good sensitivity/specificity balance
and predictive abilities [27]. Nevertheless, these strat-
egies still do not directly address the relation between
repositioning and interface pressure.
Since inadequate pressure redistribution is recognized
as a major risk factor for the development of pressure
ulcers, continuous pressure imaging (“CPI”) of the inter-
face pressure between the body and support surface
could play a role in an overall preventive strategy for
pressure ulcers. A thin mattress cover with embedded
interface pressure sensors and continuous monitoring
capabilities could provide real-time interface pressure
measurements over anatomical pressure points in a for-
mat viewable to healthcare providers, patients and their
families on a bedside liquid-crystal display (“LCD”)
monitor. Caregivers and/or healthcare providers could
utilize these data to determine when and how a patient
should be repositioned in order to redistribute optimally
the interface pressure in real time [17, 28–30]. A recent
prospective controlled study indicated that CPI could
decrease the incidence of pressure ulcers in a medical
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intensive care unit [31]. In this study, only 0.9 % of pa-
tients with the intervention developed pressure ulcers
graded at Stage II, as compared to 4.8 % of the patients
in the control group who developed them, also at the
Stage II level. In a another study over a 2-month period,
only one patient (0.03 %) in the group of patients placed
on beds with a continuous bedside pressure mapping
(CBPM) system developed a pressure ulcer, whereas 16
patients (5 %) of the historical control group of patients
placed on the same beds without CBPM (P = 0.001) [32].
Further research is required to assess whether this tech-
nology can have similar positive effects in other care set-
tings [28].
This study will use XSENSOR Technology Corpora-
tion’s ForeSite PT™ Patient Turn System (referred to as
the “ForeSite PT™ system”), a patient repositioning
reminder system utilizing CPI technology through a
pressure-sensing mattress cover, to test the efficacy of
this approach in reducing interface pressure among at-
risk hospitalized patients. Our team has previously
undertaken an evaluation of the ForeSite PT™ system,
demonstrating a positive effect of the technology on pur-
poseful turning of patients [33]. However, the goal of
this prior study was not to measure changes in actual
interface pressure. This proposed study will build on our
previous XSENSOR research to test the efficacy of CPI
in reducing interface pressure for at-risk patients. As the
most recent Canadian publication on estimates of pres-
sure ulcer occurrence is relatively outdated [1], this
study will provide updated data as well as help inform
the Canadian context.
The primary study objective is to test the efficacy of a
CPI system (ForeSite PT™ system) in its ability to reduce
interface pressure as reflected by a composite interface
pressure analysis.
Secondary objectives include the following:
1. to assess whether CPI reduces the incidence of
pressure-related tissue changes,
2. to determine the minimum interface pressure
associated with higher risk for pressure ulcer
development, and
3. to assess healthcare provider and patient perceptions
of this CPI system.
Specifically, the study will address the following
research questions:
1. Is CPI efficacious in reducing interface pressure by
assisting healthcare providers in determining the
need and type of patient turning/repositioning that
would result in lower interface pressure?
2. Does the application of CPI reduce the incidence of
pressure-related skin changes?
3. Does interface pressure correlate with clinical
outcomes?
4. What are the perceptions (both positive and
negative) of healthcare providers to CPI with regard
to the functionality, ease of use and interpretation of
pressure data on the monitor?
5. What are the perceptions (both positive and
negative) of patients (and if appropriate, family
members) to CPI (including mattress cover and
monitor display of their pressure points)?
Methods/Design
Ethics approval for this study was obtained from the
Conjoint Health Research Ethics Board of the University
of Calgary (REB13-0794).
Trial design
The trial will take place in a tertiary acute care center
situated in a major urban center. Participants will be re-
cruited from nursing units that care for patients with a
high risk of pressure ulcer development, including acute
medical, neurology, neurosurgery and intensive care
units. A parallel, two-group, randomized controlled de-
sign will be utilized to assess the effect of CPI on inter-
face pressure, pressure-related skin and soft tissue
changes and the perceptions of healthcare providers and
patients. Eligible consenting inpatients will be randomly
allocated to either one of two groups in a ratio of 1:1
and then followed for 3 days (72 h) or until discharge.
The intervention group will have the ForeSite PT™ sys-
tem and the LCD monitor turned on to provide visual
feedback to the healthcare providers while collecting
continuous interface pressure data. The control group
will have the ForeSite PT™ system turned on for collect-
ing continuous interface pressure data, but the LCD
monitor will be turned off so as not to provide visual
feedback to the healthcare providers. As a safeguard
against use of the monitor for visual feedback among
the control group, the monitor’s brightness controls will
be adjusted to limit visibility and a cover will be placed
over the monitor. Interface pressure readings will be an-
alyzed using hourly snapshot samples of continuous
interface pressure recordings. Clinical outcomes will be
obtained at baseline (within 24 h of admission) and on
the third day of the trial. The perceptions of patients
allocated to the intervention group and the perceptions
of healthcare providers each time a patient in their care
is allocated to the intervention group will be measured
on the third day. A subset of 60 participants from the
study (30 intervention, 30 control) will have data collec-
tion until their discharge from the hospital in order to
allow for a longer duration for clinical outcomes to be
evaluated.
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Participants
Recruitment
The charge nurse, and/or the patient care manager, and/
or clinicians on their respective units, will facilitate the
identification of eligible inpatients by a daily review of
new admissions. After an eligible patient has been identi-
fied, the research nurse or the research assistant will ask
him or her (or a proxy decision-maker, if not capable of
consenting), if he or she would be interested in participat-
ing in a study to evaluate a pressure sensing technology
that may provide real-time feedback to healthcare pro-
viders. If the patient agrees to participate, he or she will be
asked to provide written informed consent prior to being
enrolled in the study. Once the patient provides written
informed consent, the research nurse will set up the CPI
system, including placing the sensor mattress cover under
the linen and mounting the LCD monitor to the headwall.
The research nurse will ensure that the sensor mattress
cover and monitor are functioning properly on a daily
basis and will instruct housekeeping on sterilization prac-
tices of the device components.
Eligibility
The selection of patients will be based on the following
inclusion and exclusion criteria.
The inclusion criteria are as follows:
1. Adult males or females, with a minimum age of
18 years old.
2. Expected to have a length of stay on the unit of at
least 3 days.
3. Require assistance with bed mobility or completely
dependent for bed mobility as determined by the
“Bed” components in the de Morton Mobility Index
(DEMMI).
Eligible patients would meet the following criteria:
a. Unable (score of “0”) to bridge, roll onto their
side, and sit from lying supine.
b. Unable (score of “0”) to bridge and roll onto their
side, and requires minimal
c. Able (score of “1”) to bridge, unable to roll onto
their side (score of “0”), and requires minimal
assistance and/or supervision with sitting from
lying supine.
4. Capacity to provide consent, or have a surrogate
decision-maker to provide consent on their behalf.
5. Not near the end of life within 3 days of enrollment
in the study.
The exclusion criteria are as follows:
1. Have a planned admission to another unit (including
those identified as a setting for data collection in the
study) within three days of enrollment in the study.
2. Sleep in a chair at night.
3. Any patients whose clinical care would be negatively
impacted if turned or repositioned.
Setting
This trial will take place in at least five inpatient nursing
units at the Foothills Medical Centre, a tertiary care
institution, in Calgary, Alberta, Canada. The five units
include, but are not limited to the following: 1) Unit 36
and Unit 37 in the Special Services Building, the internal
medicine services that care for vulnerable general med-
ical inpatients with immobility arising from complex
multisystem medical illness; 2) the intensive care unit
(“ICU”) that cares for sedated and immobilized patients
requiring life support for prolonged periods of time; and 3)
Unit 101 and Unit 112, acute neurological units that care
for patients with mobility impairment resulting from
neurological illnesses, spinal cord and/or significant head
injuries. These units were chosen due to their high concen-
tration of patients at high-risk of pressure ulcer develop-
ment and the feasibility of data collection, as demonstrated
by a pilot study that was performed by our group in prep-
aration for this RCT.
Intervention
All eligible consenting inpatients will receive usual care
by their healthcare providers and undergo continuous
interface pressure monitoring by the ForeSite PT™ sys-
tem throughout all 3 days of enrollment or until dis-
charge. Three days was chosen as the duration for four
reasons: 1) it is the average length of stay in the in-
patient units where this trial is taking place, and extend-
ing the enrollment period beyond 3 days when patients
may be transferred to another nursing unit may intro-
duce more variability in the nursing practice and care
and would not be feasible if they are discharged to
another facility or home; 2) expert consensus of the
investigation team deemed that 3 days was sufficient
for pressure-related skin and soft tissue changes to
develop; 3) there is likely to be change in nursing
shifts and personnel beyond 3 days, thereby introdu-
cing more variables; and 4) as interface pressure will
be continually collected throughout the enrollment
period, a longer duration would result in an ex-
tremely large volume of data. Thus, 3 days will allow
for optimal data collection while maintaining feasibil-
ity of participant enrolment.
Following the 3-day enrollment period, a subset of 60
participants who have not yet been discharged will con-
tinue to undergo continuous interface pressure monitor-
ing until they are discharged from the hospital. This
subset of participants will enrich the dataset by provid-
ing a longitudinal perspective that can inform a potential
larger multicenter RCT.
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XSENSOR Technology Corporation’s ForeSite PT™
Patient Turn System (referred to as the “ForeSite PT™
system”) continuously monitors the interface pressure
and provides CPI that quantifies real-time interface pres-
sure information (Fig. 1). It also provides patient turn
tracking to assist with management of the patient turn
schedule by alerting healthcare providers and/or care-
givers to the location of body areas that have experi-
enced the greatest exposure and when the next turn/
repositioning is due as per pre-set alerts.
The ForeSite PT™ system consists of two parts: a thin,
flexible sensor mattress cover that is positioned under
the hospital linen (that is, fitted mattress sheet) and an
LCD monitor that is mounted to the head of the bed.
The LCD monitor displays color information about the
patient surface pressure on the bed and provides risk in-
formation determined by the length of time pressure
had persisted in any location.
The measurements for interface pressure will be
achieved by the continuous collection of interface
pressure readings by the ForeSite PT™ system’s pres-
sure sensing mattress cover, which is a capacitive sen-
sor array with a spatial resolution of 0.625. There are
52 rows x 118 columns for 6,136 sensing points. The
ForeSite PT™ system’s software continuously samples
interface pressure at a rate of 1 Hz, which can then
be extracted for analysis (Fig. 2). The XSENSOR Pres-
sure Exposure Analyzer Tool (PEAT) will be used to
process sessions of pressure readings collected by the
ForeSite PT™ system. The new data file produced by
PEAT is in a proprietary binary format, and can be
exported to TXT or CSV formats for import into a
spreadsheet program for analysis (Fig. 3). This will be
achieved by the sampling of pressure readings at
hourly intervals regardless of whether there has been
turning/repositioning when the ForeSite PT™ system’s
LCD monitor is turned on and when it is turned off.
Treatment group
Inpatients assigned to the treatment group will have the
ForeSite PT™ system’s LCD monitor turned on (that is,
real-time images of interface pressure will be displayed
on the monitor) during their enrollment in the trial.
Control group
Inpatients assigned to the control group will have the
ForeSite PT™ system’s LCD monitor turned off and hid-
den so that it cannot be accessed by healthcare providers
wanting to see pressure readings (that is, real-time im-
ages of interface pressure will not be displayed on the
monitor). As the ForeSite PT™ system will continue to
record interface pressure with the display turned off, this




The primary outcome is as indicated:
1. A composite of interface pressure analysis that
reflects the distribution of interface pressure at
predetermined time intervals.
These measures include:
a. Peak pressure of any given pressure-reading sample.
b. Absolute number of sensels with pressure readings
greater than 40 mmHg.
c. Average interface pressure (excluding sensels with
0 mmHg reading).
d. Proportion of patients that have pressure readings
greater than 40 mmHg.
Definitions of these measures can be found in Table 1.
Given the paucity of literature, this composite measure
Fig. 1 ForeSite PT™ Patient Turn System
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allows for a greater understanding of the relationship be-
tween interface pressure and repositioning strategies.
While pressure ulcer incidence may be of primary clin-
ical interest, interface pressure measurements are quan-
tifiable and are recognized to be a major risk factor for
pressure ulcer development. For the purposes of this
trial, we would like to focus on interface pressure as the
primary outcome, as using pressure ulcer incidence as a
primary outcome would likely involve many other fac-
tors that would influence the development of pressure
ulcers, requiring a much higher sample size than what
this single-site study can provide.
The pressure threshold of 40 mmHg was selected based
on analysis of pilot data (not shown) that showed a pressure
reading of 39.88 mmHg was at the 90th percentile of the
distribution of the pressure measured by the ForeSite PT™
system. This threshold was also considered relevant as
existing research indicated that this it has clinical concord-
ance with interface pressure between 30 and 32 mmHg, a
range within which there is compromised capillary flow.
Fig. 2 A pressure imaging session processed by XSENSOR Pressure Exposure Analyzer Tool (PEAT)
Fig. 3 Processed pressure imaging session extracted in CSV format
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Secondary outcomes
Secondary outcomes are as described below:
1. A clinical endpoint that measures pressure-related
skin and soft tissue changes
including:
a. Skin discoloration.
b. Localized tenderness without skin breakdown.
c. Stage I and II (partial thickness) pressure ulcer
formation.
d. Stage III and IV (full thickness) pressure ulcer
formation.
e. Unstageable/unclassified: full thickness skin or tissue
loss - depth unknown.
f. Suspected deep tissue injury - depth unknown.
g. Presence of any skin, wound or underlying bone
infection (that is, cellulitis, infected ulcers or
osteomyelitis).
Endpoints c, d, e and f will be identified according to
the NPUAP’s pressure ulcer staging system [34]. This
outcome will be measured by a clinical head-to-toe skin
assessment for detection of pressure-related skin
changes and for overt ulceration by the research nurse.
This assessment will be conducted within 24 h of admis-
sion and on the third day of enrollment. This informa-
tion will be noted on a form, which requires the
research nurse to circle the skin areas where the patient
may have skin changes or a pressure ulcer. They will
label the circled area with the numbers 1 to 9 that cor-
respond to predetermined categories of pressure-related
skin changes and stages of pressure ulcer development
(Table 2).
1. Perceptions (both positive and negative) of
healthcare providers caring for patients allocated to
the treatment group to the CPI system. This
outcome will be measured by a survey consisting of
17 close-ended and open-ended questions about
prior experience with pressure mapping technology,
functionality, ease of use, and interpretation of pressure
data on the LCD monitor. These questions were
utilized in a prior pilot study assessing healthcare
providers’ perceptions to the interface pressure
information provided on the LCD monitor, and
the impact of this information on patient care.
The survey will be administered to healthcare
providers approximately three months after
enrollment has begun on their respective units,
and will take approximately ten minutes to
complete.
2. Perceptions (both positive and negative) of patients
(and if appropriate, family members) allocated to the
treatment group to the CPI system. This outcome
will be measured by a survey consisting of seven
close-ended and open-ended questions about prior
and current experience with CPI (including sensor
mattress cover and monitor display of their pressure
distribution) on their care and comfort. The survey
will be administered by the research nurse or the
research assistant on the patient’s third day of
enrollment and will take approximately 10 minutes
to complete.
Additional data collection
To establish a patient profile at baseline (within 24 h of
admission), a pressure ulcer risk assessment with the
Braden Scale will be conducted, and demographic and
medical history information will be collected from pa-
tient charts. Table 3 specifies the information that will
be collected at baseline, on the second day of enrollment
and on the third day and/or last day of enrollment
(depending on whether the participant is in the main
sample or the subsample). The risk assessment will
be conducted by the research nurse, and demographic
and medical history information will be collected by
either the research nurse or the research assistant.
The Braden Scale [26], which was developed to as-
sist healthcare providers with assessing a patient’s
level of risk for pressure ulcer development and in-
form the course of a particular treatment, will be
administered to each patient to determine their indi-
vidual risk. It is a summated rating scale composed of
Table 1 Definitions of summary measures of interest
Measure of interest Description/definition
Mean Σpi/n - average of pressure readings
Peak Pmax - maximum pressure reading
Sum Σpi - sum of all pressure readings
Count ≥40 mmHg Count of all pressure readings ≥40 mmHg
Standard deviation for average of averages Headrick, T. C. (2010). Statistical Simulation: Power Method Polynomials and other Transformations.
Boca Raton, FL: Chapman & Hall/CRCVA1 ¼ m
2V1þn2V2‐nV1‐nV2‐mV1‐mV2þmnV2þmn M1‐M2ð Þ2
nþm‐1ð Þ nþmð Þ 5:38ð Þ
Average of averages weighted avg. = [(no. of M)(AVG-of-M) + (no. of R)(AVG-of-R)]/ (total no. of M and R together)
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six subscales: sensory perception, activity, mobility, mois-
ture, friction and nutrition. Each subscale is scored from 1
to 3 or 1 to 4, for a total score that ranges from 6 to 23. A
lower total score indicates a lower level of functioning and
therefore a higher level of risk for pressure ulceration.
In addition, on the third and last day of enrollment, the
research nurse or research assistant will observe and note
the pressure ulcer prevention and management strategies
that were used (for example, wedges) for each participant.
Sample size
A total of 678 patients will be recruited from Units 36, 37,
101, 112 and the ICU for enrollment in the trial, in order
to randomize 339 patients to each of the intervention and
control arms. Sample size estimates for the primary out-
come indicate a need for 308 patients in each of the inter-
vention and control arms, in addition to 31 patients per
arm to allow for 10 % attrition. This is based on an ana-
lysis of pilot data (not shown) that showed a mean pres-
sure of 136 mmHg (SD = 62 mmHg) and allows for the
detection of a statistically significant 15 % relative decrease
in the count of sensels over 40 mmHg (β 0.2 that is, Type
II error rate).
The subsample of 60 participants will be purposively
sampled from the same units to ensure that a wide range
of length of stays will be represented. Because the ob-
jective of extracting a subsample of participants is to in-
form a potential larger multicenter trial rather than to
Table 2 National Pressure Ulcer Advisory Panel (NPUAP) categories and staging of pressure ulcers and other skin appearance
changes to determine pressure of pressure ulceration and severity and development of other skin condition changes
Numbered Labels Descriptions
1. Pressure-related blanchable erythema (excluding
dermatitis, cellulitis, and trauma)
Intact skin with redness; skin remains blanchable on compression, potentially reversible
change
2. Stage I pressure ulcer (nonblanchable erythema) Intact skin with nonblanchable redness of a localized area, usually over a bony prominence.
Darkly pigmented skin may not have visible blanching; its color may differ from the
surrounding area. The area may be painful, firm, soft, warmer or cooler as compared to
adjacent tissue. Category I may be difficult to detect in individuals with dark skin tones. May
indicate “at risk” persons.
3. Stage II pressure ulcer (partial thickness skin loss) Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink wound bed,
without slough. May also present as an intact or open/ruptured serum-filled or sero-sanginous
filled blister. Presents as a shiny or dry shallow ulcer without slough or bruising*. This category
should not be used to describe skin tears, tape burns, incontinence associated dermatitis, ma-
ceration or excoriation. *Bruising indicates deep tissue injury.
4. Stage III pressure ulcer (full thickness skin loss) Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon and muscle are
not exposed. Slough may be present but does not obscure the depth of tissue loss. May
include undermining and tunneling. The depth of a Category/Stage III pressure ulcer varies by
anatomical location. The bridge of the nose, ear, occiput and malleolus do not have (adipose)
subcutaneous tissue and Category/Stage III ulcers can be shallow. In contrast, areas of
significant adiposity can develop extremely deep Category/Stage III pressure ulcers. Bone/
tendon is not visible or directly palpable.
5. Stage IV pressure ulcer (full thickness tissue loss) Full thickness tissue loss with exposed bone, tendon or muscle. Slough or eschar may be
present. Often includes undermining and tunneling. The depth of a Category/Stage IV
pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput and
malleolus do not have (adipose) subcutaneous tissue and these ulcers can be shallow.
Category/Stage IV ulcers can extend into muscle and/or supporting structures (for example,
fascia, tendon or joint capsule) making osteomyelitis or osteitis likely to occur. Exposed bone/
muscle is visible or directly palpable.
6. Unstageable/Unclassified: Full thickness skin or
tissue loss - depth unknown
Full thickness tissue loss in which actual depth of the ulcer is completely obscured by slough
(yellow, tan, gray, green or brown) and/or eschar (tan, brown or black) in the wound bed.
Until enough slough and/or eschar are removed to expose the base of the wound, the true
depth cannot be determined; but it will be either a Category/Stage III or IV. Stable (dry,
adherent, intact without erythema or fluctuance) eschar on the heels serves as “the body’s
natural (biological) cover” and should not be removed.
7. Suspected deep tissue injury - depth unknown Purple or maroon localized area of discolored intact skin or blood-filled blister due to damage
of underlying soft tissue from pressure and/or shear. The area may be preceded by tissue that
is painful, firm, mushy, boggy, warmer or cooler as compared to adjacent tissue. Deep tissue
injury may be difficult to detect in individuals with dark skin tones. Evolution may include a
thin blister over a dark wound bed. The wound may further evolve and become covered by
thin eschar. Evolution may be rapid exposing additional layers of tissue even with optimal
treatment.
8. Infection - cellulitis around pressure ulcer This presents as redness, warmth and swelling in the skin around the pressure ulcers.
9. Infection - pressure ulcer wound base infection,
osteomyelitis
This presents as drainage (potentially purulent) with strong odor from the base of the pressure
ulcer. May have necrotic material as wound base.
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sufficiently power a substudy, 60 participants were
deemed to be sufficient to provide a longer term snap-
shot of patients who have lengths of stay longer than
3 days.
Randomization
A randomized treatment allocation table was created
on 24 November 2014, using sealedenvelope.com [35].
The seed was 57107341298070; the treatment groups
were: Screen ON and Screen OFF, Block Sizes were 4,
6 and 8; the length of the list was 5024, and were
stratified by unit: ICU, Unit 101, Unit 111, Unit 112,
Unit 36, Unit 37.
Study data will be collected and managed using REDCap
[36] electronic data capture tools hosted at the University
of Calgary in collaboration with the Cumming School of
Medicine. The randomization module was enabled in
REDCap, and the allocation table produced by Sealed
Envelope was imported into the web-based application.
Patients will be entered into the database and randomized
according to their care unit.
Blinding
Allocation will be independently undertaken, and con-
cealed from principal investigator, co-investigators and
the research coordinator, who will be involved in data
Table 3 Schedule of data collection
Data to be collected Day 1: Baseline (within
24 hours of admission)
Day 2: Interim Day 3: Enrollment termination
(within 24 hours)*
Continuous interface pressure Yes Yes Yes
Clinical head-to-toe skin assessment Yes No Yes
Braden Scale Yes No Yes
Level of bed mobility Yes No Yes
Charlson comorbidity index Yes No No
Complete blood count (CBC) Yes No No
Pre-albumin Yes No No
Albumin Yes No No
Creatinine Yes No No
Liver function test results (alkaline phosphatase; aspartate aminotransferase
(AST))
Yes No No
C reactive protein (CRP) Yes No No
Glycosylated hemoglobin Yes No No
Body mass index (BMI) Yes No No
Reason for admission/diagnoses Yes No No
Bladder management Yes No No
Bowel management Yes No No
History of cancer and treatment Yes No No
History of cardiovascular disease Yes No No
History of renal failure Yes No No
Use of immunosuppressive medications Yes No No
Pressure ulcer history Yes No No
Smoking history Yes No No
Illicit drug use Yes No No
Demographics (that is, sex, date of birth, race) Yes No No
Perceptions of healthcare providers of patients in the treatment group** No No No
Perceptions of patients (and/or their family members) in the treatment group No No Yes
Pressure ulcer prevention and treatment methods No No Yes
*For the subset sample of 60 participants, this information will be collected on the day of discharge from the hospital, as well as on weekly basis if their length of
stay exceeds one week
**This information will be collected approximately 3 months after enrollment has begun on their respective units to ensure healthcare providers have sufficient
exposure to the technology
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analysis. The research nurse and the research assistant
will both be involved in patient recruitment, the
randomization process and data collection, and will not
be blinded to treatment allocations. Outcome assess-
ment for clinical data will not be blinded as the outcome
is objective, and it has been found that there is little evi-
dence of bias in trials with objective outcomes [37]. It
will not be possible to blind patients and healthcare pro-
viders because they will be able to see if the LCD moni-
tor that displays information about the patient’s surface
pressure on the bed is mounted to the headwall.
Analysis and statistical methods
Data analysis will use univariate statistics to summarize
changes in pressure distribution as per the interface pres-
sure feedback collected by the CPI system. Chi-square and/
or Fisher exact tests will be used for between-group (that is,
intervention and control groups) comparisons of the pri-
mary outcome and the secondary outcomes, and the
Wilcoxon rank sum test for between-group comparison
of strategic shifting. Chi square and t-tests will be
used to compare baseline characteristics between
groups, and both linear least squares regression and lo-
gistic regression will be used for adjusted analyses if there
are notable between-group differences for important base-
line characteristics. Correlation between pressure distribu-
tion (the study’s primary endpoint) with the hard clinical
outcome (pressure ulceration and pressure-related skin
appearance changes) will also be explored.
Simple descriptive statistics will be used to summarize
close-ended survey data, whereas open-ended survey data
will be thematically analyzed and reported qualitatively.
Missing data will be dealt with by analyzing data using an
as-treated approach. A sensitivity analysis will explore the
results as per protocol (all patients regardless of missing
data) to determine bias that might exist. Depending on the
amount of missing data, imputing missing values may be
performed and models compared.
Discussion
While it is generally accepted that prolonged interface pres-
sure contributes to the development of ulcers, limited re-
search exists in this area, particularly on the role of CPI.
This is the first randomized controlled trial to assess the ef-
ficacy of CPI for reducing interface pressure and on the de-
velopment of pressure-related skin and soft tissue changes.
This RCT will compare the interface pressure and
pressure-related skin and soft tissue changes between the
intervention group, which will have the ForeSite PT™ sys-
tem with the LCD monitor turned on to provide visual
feedback through CPI to the clinicians, and the control
group, which will have the ForeSite PT™ system with the
LCD monitor turned off, therefore not providing visual
feedback or CPI to the clinicians. Both groups will undergo
continuous interface pressure data collection and clinical
assessment. Thus, the present RCT will contribute to a bet-
ter understanding of the role of CPI in interface pressure
management and, subsequently, the prevention and man-
agement of pressure ulcers.
While this RCT in itself is not likely to be sufficient to
inform health system decision making on whether to
purchase CPI systems en masse, the findings could pro-
vide greater understanding of the use of this technology
in clinical practice. This study also has the potential to
increase our understanding of the relation between
interface pressure and skin and tissue changes resulting
from the exposure to prolonged pressure. A much larger
trial would be required in subsequent stages to deter-
mine the impact of CPI on the hard clinical endpoint of
overt pressure ulceration, that is, the clinical outcome
that we are ultimately trying to prevent. The present
RCT described here will build significantly on previous
research on interface pressure and pressure ulcer devel-
opment, and it will clarify the role of CPI in modifying
interface pressures, an important intermediate goal in
the prevision pressure ulcers.
Trial status
To date, a total of 117 participants have been recruited; of
these, 105 have been included in the trial, and 12 were
excluded.
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